Nepal | September 29, 2020

Russia’s COVID-19 vaccine showed antibody response in initial trials

Reuters
Share Now:
  • Russia has licensed potential coronavirus vaccine
  • The Lancet has published results of early-stage trials
  • Russian wealth fund chief says results answer critics

MOSCOW: Russia’s “Sputnik-V” COVID19 vaccine produced an antibody response in all participants in early-stage trials, according to results published on Friday by The Lancet medical journal that were hailed by Moscow as an answer to its critics.

The results of the two trials, conducted in June-July this year and involving 76 participants, showed 100% of participants developing antibodies to the new coronavirus and no serious side effects, The Lancet said.

A handout photo shows an employee demonstrating vials with “Gam-COVID-Vac” vaccine against the coronavirus disease (COVID-19), developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), during its production at Binnopharm pharmaceutical company in Zelenograd near Moscow, Russia August 7, 2020. Picture taken August 7, 2020. Photo: The Russian Direct Investment Fund (RDIF)/Andrey Rudakov/Handout via Reuters

Russia licensed the two-shot jab for domestic use in August, the first country to do so and before any data had been published or a large-scale trial begun.

“The two 42-day trials – including 38 healthy adults each – did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” The Lancet said.

“Large, long-term trials including a placebo comparison, and further monitoring are needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID19 infection,” it said.

The vaccine is named Sputnik-V in homage to the world’s first satellite, launched by the Soviet Union. Some Western experts have warned against its use until all internationally approved testing and regulatory steps have been taken.

But with the results now published for the first time in an international peer-reviewed journal, and with a 40,000-strong later-stage trial launched last week, a senior Russian official said Moscow had faced down its critics abroad.

“With this (publication) we answer all of the questions of the West that were diligently asked over the past three weeks, frankly with the clear goal of tarnishing the Russian vaccine,” said Kirill Dmitriev, the head of the Russian Direct Investment Fund (RDIF), Russia‘s sovereign wealth fund, which has backed the vaccine.

“All of the boxes are checked,” he told Reuters. “Now… we will start asking questions of some of the Western vaccines.”

Commenting on the results of the early-stage trials, lead author Dr Naor Bar-Zeev of the International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, USA said the studies were “encouraging but small”.

Bar-Zeev, who was not involved in the study, said “clinical efficacy for any COVID19 vaccine has not yet been shown.”

“The report is a case of ‘so far, so good’,” Brendan Wren, Professor of Microbial Pathogenesis at London’s School of Hygiene and Tropical Medicine said.


RACE TO DEVELOP VACCINE

Dmitriev said at least 3,000 people had already been recruited for the large-scale trial of the Sputnik-V vaccine launched last week, and initial results were expected in October or November this year.

Health minister Mikhail Murashko has said Russia will start mass inoculation from November or December, with a focus on high-risk groups. It will take nine to 12 months to vaccinate the majority of the population, said Alexander Gintsburg, director of the Gamaleya Institute which developed the vaccine.

Governments and big pharmaceutical firms are racing to develop a vaccine to end the COVID19 pandemic, which has killed more than 850,000 people globally and infected around 26 million.

Over half a dozen drugmakers are already conducting advanced clinical trials, each with tens of thousands of participants. Several, including Britain’s AstraZeneca and U.S. drugmakers Moderna and Pfizer expect to know if their COVID19 vaccines work and are safe by the end of 2020.

The Lancet said the early-stage trials suggested the Sputnik-V vaccine produced a response in a component of the immune system known as T cells.

Scientists have been scrutinising the role played by T cells in battling coronavirus infection, with recent findings showing these cells may provide longer-term protection than antibodies.

The Sputnik-V vaccine is administered in two doses, with each based on a different vector that normally causes the common cold: human adenoviruses Ad5 and Ad26.

Some experts have said using this delivery mechanism could make a COVID19 vaccine less effective, as many people have already been exposed to the Ad5 adenovirus and developed immunity to it.

Russia has said it expects to produce between 1.5 million and 2 million doses per month of its potential vaccine by the end of the year, gradually increasing production to 6 million doses a month.


Follow The Himalayan Times on Twitter and Facebook

Recommended Stories:

More from The Himalayan Times:

leicester city, Jamie Vardy

Vardy treble inspires Leicester to 5-2 win over Man City

MANCHESTER: A Jamie Vardy hat-trick coupled with goals from James Maddison and Youri Tielemans steered Leicester City to a stunning 5-2 win at Manchester City on Sunday and kept them top of the Premier League with a maximum nine points from three games. City had not conceded five go Read More...

Prominent personalities urge govt to save Dr KC

KATHMANDU, SEPTEMBER 27 A group of 33 citizens, who once held prominent positions, have urged the government to save the life of Dr Govinda KC, who has been staging a fast-unto-death demanding reform in the medical education sector for the past 14 days. Issuing a joint press release today they Read More...

La Liga, barcelona, Lionel Messi

Messi back in scoring business in dream start for Koeman

BARCELONA: Lionel Messi was back in scoring business for Barcelona on Sunday, leading them to a resounding 4-0 win at home against Villarreal in a near-perfect La Liga opener for the Catalans under new coach Ronald Koeman. Teenage forward Ansu Fati was in inspirational form for Barca, c Read More...

Atletico Madrid, Luis Suarez, La Liga

Suarez scores twice, gets assist as Atletico lay down marker

MADRID: Luis Suarez had a stunning impact on his debut for Atletico Madrid following his move from Barcelona, scoring twice and providing an assist as his side crushed Granada 6-1 at home in their first game of the La Liga season on Sunday. Suarez, who only completed his switch from Barc Read More...

Replace all Cabinet ministers: NCP Co-chair Dahal

KATHMANDU, SEPTEMBER 27 Co-chairs of the ruling Nepal Communist Party (NCP) — Pushpa Kamal Dahal and Prime Minister KP Sharma Oli — met today to discuss Cabinet reshuffle. A source close to Dahal told THT that Dahal asked Oli to replace all the ministers in his Cabinet, but the PM did not Read More...

CCTV surveillance/monitoring of kathmandu traffic

People told to be aware of fraudsters

KATHMANDU, SEPTEMBER 27 Police have urged people, especially those going abroad or returning from foreign countries, to be aware of fraudsters offering to exchange dollar bills at a rate cheaper than the market price. According to statistics with the Metropolitan Police Office, at least such 1 Read More...

Tourism activities resume in Pokhara

POKHARA, SEPTEMBER 27 Tourism industry has shown signs of revival after six months of the COVID-19 induced lockdown was relaxed in Pokhara. Mardi Himal Trek has witnessed mobility of tourists. Number of domestic tourists along the trekking route is on the rise, according to Raju Poudel, owner Read More...

NCB arrests three with 10 kg opium in Pokhara

KATHMANDU, SEPTEMBER 27 The Narcotics Control Bureau, Koteshwor, arrested three persons with 10 kilograms opium from Pokhara Metropolitan City, Kaski, yesterday. They have been identified as Gaja Pun, 50, and Chakkar Bahadur Pun, 40, of Eastern Rukum and Rabi Gurung, 24, of Gorkha. Superint Read More...